Arthritis Research & Therapy

SCIE-ISI SCOPUS (2003-2023)

  1478-6354

 

 

Cơ quản chủ quản:  BioMed Central Ltd. , BMC

Lĩnh vực:
ImmunologyRheumatologyImmunology and Allergy

Các bài báo tiêu biểu

Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases
Tập 11 Số 3 - Trang 229 - 2009
Sherine E. Gabriel, Kaleb Michaud
Rheumatic Diseases in China
Tập 10 Số 1 - Trang R17 - 2008
Qing Yu Zeng, Ren Chen, John Darmawan, Zheng Xiao, Chen Su, Wigley Rd, Shun Le Chen, Zhang Nai
IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/Akt-dependent pathways
Sung Yeoun Hwang, Ju‐Young Kim, Kyoung-Woon Kim, Mi-Kyung Park, Young Myoung Moon, Wan‐Uk Kim, Ho-Youn Kim
Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1β-stimulated fibroblast-like synoviocytes and in rat arthritis models
- 2009
Jun Soo Bang, Da Hee Oh, Hyun Rim Choi, Bongjun Sur, Sung‐Jig Lim, Jung Yeon Kim, Haesik Yang, Myung Chul Yoo, Dae‐Hyun Hahm, Kyoung Soo Kim
Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility
Tập 16 Số 3 - Trang R122 - 2014
Chanchal Sur Chowdhury, Stavros Giaglis, Ulrich A. Walker, Andreas Buser, Sinuhe Hahn, Paul Hasler
Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints
Tập 8 - Trang 1-9 - 2006
Uffe Møller Døhn, Bo J Ejbjerg, Michel Court-Payen, Maria Hasselquist, Eva Narvestad, Marcin Szkudlarek, Jakob M Møller, Henrik S Thomsen, Mikkel Østergaard
The objective of the study was, with multidetector computed tomography (CT) as the reference method, to determine whether bone erosions in rheumatoid arthritis (RA) metacarpophalangeal (MCP) joints detected with magnetic resonance imaging (MRI) and ultrasonography (US), but not with radiography, represent true erosive changes. We included 17 RA patients with at least one, previously detected, radiographically invisible MCP joint MRI erosion, and four healthy control individuals. They all underwent CT, MRI, US and radiography of the 2nd to 5th MCP joints of one hand on the same day. Each imaging modality was evaluated for the presence of bone erosions in each MCP joint quadrant. In total, 336 quadrants were examined. The sensitivity, specificity and accuracy, respectively, for detecting bone erosions (with CT as the reference method) were 19%, 100% and 81% for radiography; 68%, 96% and 89% for MRI; and 42%, 91% and 80% for US. When the 16 quadrants with radiographic erosions were excluded from the analysis, similar values for MRI (65%, 96% and 90%) and US (30%, 92% and 80%) were obtained. CT and MRI detected at least one erosion in all patients but none in control individuals. US detected at least one erosion in 15 patients, however, erosion-like changes were seen on US in all control individuals. Nine patients had no erosions on radiography. In conclusion, with CT as the reference method, MRI and US exhibited high specificities (96% and 91%, respectively) in detecting bone erosions in RA MCP joints, even in the radiographically non-erosive joints (96% and 92%). The moderate sensitivities indicate that even more erosions than are seen on MRI and, particularly, US are present. Radiography exhibited high specificity (100%) but low sensitivity (19%). The present study strongly indicates that bone erosions, detected with MRI and US in RA patients, represent a loss of calcified tissue with cortical destruction, and therefore can be considered true bone erosions.
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
Tập 8 Số 1
Juan J. Gómez‐Reino, Loreto Carmona
Abstract

The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard ratio (HR) for discontinuation 0.55 (95% confidence interval (CI), 0.34–0.84)), and worse in patients older than 60 years (HR 1.10 (95% CI 0.97–2.49)) or who were treated with infliximab (HR 3.22 (95% CI 2.13–4.87)). In summary, in patients who require continuous therapy and have failed to respond to a TNF antagonist, replacement with a different TNF antagonist may be of use under certain situations. This issue will deserve continuous reassessment with the arrival of new medications.

The sympathetic nervous response in inflammation
- 2014
Georg Pongratz, Rainer H. Straub